Drug discovery

EQS-News: Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing

Retrieved on: 
Mercredi, avril 10, 2024
AI, Patient, Partex Group, Motion, Hope, Drug discovery, Pharmaceutical industry

Frankfurt, Germany; 14 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, aimed at using Partex’s advanced AI technology to enhance the value of Sanofi's out-licensing portfolio.

Key Points: 
  • Frankfurt, Germany; 14 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, aimed at using Partex’s advanced AI technology to enhance the value of Sanofi's out-licensing portfolio.
  • Through meticulous indication expansion, prioritization, and lab validation studies, the collaboration endeavours to uncover fresh prospects for Sanofi’s out-licensing portfolio.
  • Dr. Gunjan Bhardwaj, CEO of Partex, expresses enthusiasm about this innovative milestone collaboration, stating, “Our collaboration with Sanofi exemplifies our dedication to driving innovation in drug discovery.
  • Partex will receive an upfront cash component at the start of the collaboration and an opportunity to receive additional future financial incentives.

EQS-News: Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Retrieved on: 
Mercredi, avril 10, 2024
CE, Asos, Drug discovery, Central nervous system, Patient, Ophthalmology, RNA, Research, CBO, Protein, Drug development, Medical device

EQS-News: Secarna Pharmaceuticals GmbH & Co. KG

Key Points: 
  • EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
    The issuer is solely responsible for the content of this announcement.
  • Dallas, TX, USA and Martinsried, Germany, March 20, 2024 – Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
  • “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, Global Business Strategy Leader for Ophthalmology and RNA at Celanese.
  • “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.

EQS-News: Bayer and Aignostics to collaborate on next generation precision oncology

Retrieved on: 
Mercredi, avril 10, 2024
Algorithm, Disease, Drug discovery, Intelligence, Partnership, Patient, Hospital, Artificial intelligence, Cancer, Executive Committee, AI, Biology, Bayer, Pathology, Machine learning, Pharmaceutical industry

Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

Key Points: 
  • Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.
  • The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, and Bayer’s deep expertise in discovering and developing novel oncology therapies.
  • Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare,” said Viktor Matyas, CEO of Aignostics GmbH.
  • Aignostics will receive an upfront payment and is eligible to receive success-based milestone payments and royalties on any commercialized therapies that result from the collaboration.

AI Stocks Targeting Opportunities in the Global Healthcare Market

Retrieved on: 
Mercredi, avril 10, 2024
Crypto, Depression, Mining, Algorithm, Health, Metropolis, Patient, Social media, Artificial intelligence, History, Sale, LLM, USD, Marketing, Risk, Policy, Chemistry, Renewable energy, OTCQB, Conditional sentence, Organization, Sport, Drug discovery, Hospital, Research, Unified, Publishing, News, Acquisition, Prescription, AI, Robotics, Dell Technologies, Drug development, API, Diagnosis, Pressure, Environment, Disclosure, Biology, Dell, NVIDIA, Medicine, Medical device

The AI in Healthcare market is projected to grow from USD 20.9 billion in 2024 and reach USD 148.4 billion by 2029.

Key Points: 
  • The AI in Healthcare market is projected to grow from USD 20.9 billion in 2024 and reach USD 148.4 billion by 2029.
  • Betting on healthcare as a key market, Avant Technologies, Inc. (OTCQB: AVAI) just announced the completion of its acquisition of privately-held healthcare technology and data integration services firm, Wired-4-Health.
  • "By helping healthcare companies easily build and manage AI solutions, we're enabling them to harness the full power and potential of generative AI."
  • For investors following AI stocks, the hunt is on for finding the stocks that can harness the power of AI for the next generation of healthcare.

BullFrog AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo

Retrieved on: 
Mardi, avril 9, 2024
Organization, Conference, Drug discovery, COVID-19, Patient, Research, Artificial intelligence, Classification, Personalized medicine, Medicine, Quantum, Bullfrog, Machine learning, CSO

The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.

Key Points: 
  • The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.
  • Chittenden's presentation will explain how quantum methods have been used to decipher complex disease patterns, including analysis of multi-omics cancer data and classification of severe COVID-19 patients.
  • "The research I will highlight during my presentation is a testament to the synergies between quantum computing and machine learning, offering novel solutions to longstanding challenges in biomedical sciences."
  • The Quantum Computing Symposium is a premier event for professionals in the pharmaceutical industry, highlighting the revolutionary role of quantum technologies across various sectors, including drug discovery and supply chain management.

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Retrieved on: 
Lundi, avril 8, 2024
MDM2, Apoptosis, ASH, Drug discovery, PD, Patient, Tumor microenvironment, Cancer, Doctor of Philosophy, TPD, Proteomics, AACR, Society, Therapy, Drug development, Downregulation and upregulation, VHL, STAT3, Pharmaceutical industry

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company’s unique target selection strategy and strong preclinical to clinical translation observed across the Company’s first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.

Key Points: 
  • For these reasons, STAT3 degraders may provide a solution to the development of targeted and selective drugs to address multiple STAT3 dependent pathologies.
  • Additionally, this unique mechanism of action led to induction of proinflammatory anti-tumorigenic transcriptional signatures in the tumor microenvironment.
  • This has resulted in robust antitumor activity in patients, as reported in the Company’s latest clinical update at the American Society of Hematology (ASH) Annual Meeting in December 2023.
  • The Company expects to complete both studies and share additional clinical data to inform the programs’ next development steps in 2024 at upcoming medical meetings.

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

Retrieved on: 
Lundi, avril 8, 2024
Royal, Medicine, FRS, Biochemical Society, Translational research, Wellcome Sanger Institute, Woman, Drug discovery, Trinity College, Royal Society, International, GSK, University, Membrane, Patient, Doctor of Philosophy, EMBO Gold Medal, University College London, Translation, Architecture, Therapy, Immune system, SAB, The Genetics Society, Molecular biology, Pharmaceutical industry

Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.

Key Points: 
  • Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.
  • During this time, she also collaborated with OMass’ co-founder, Professor Dame Carol Robinson, on unraveling the in vivo and in vitro assembly of soluble protein complexes.
  • Ali Jazayeri, Chief Scientific Officer at OMass Therapeutics, commented: “I look forward to working with Sarah.
  • Our previous long-standing collaboration on the assembly of soluble protein complexes demonstrates how her skillset can be complementary to our native mass spectrometry approach and can contribute to further developing our drug discovery platform.”
    Sarah Teichmann, Member of the Scientific Advisory Board of OMass Therapeutics, added: “I am thrilled to be joining OMass Therapeutics’ SAB.

Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry

Retrieved on: 
Vendredi, avril 5, 2024
Drug design, Biotechnology, Drug discovery, Artificial intelligence, Stripe, Myriad Genetics, Protein folding, Biology, Data collection, Chemistry, Therapy, Machine learning, Data, Leash, Collection

SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection. The oversubscribed round was led by Springtide Ventures with participation from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, Recursion CEO and co-founder Chris Gibson, and Recursion co-founder Blake Borgeson.

Key Points: 
  • SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.
  • To achieve this, Leash is producing bespoke, expansive datasets of protein targets binding to chemicals.
  • We believe a similar strategy will revolutionize how we approach medicinal chemistry," said Ian Quigley, CEO of Leash Biosciences.
  • "Leash's platform stands apart with its combined excellence in machine learning, experimental biology, and medicinal chemistry," said Claire Smith, Lead Investor at Springtide Ventures.

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
Mercredi, avril 3, 2024
Discovery, Epilepsy, GABAB, Senior, Glutamic acid, Dyskinesia, Glutamate (neurotransmitter), Drug discovery, Partnership, TBI, SIX, Chronic cough, NAM, CHF5, Therapy, DSM-IV codes, Janssen, Safety, ADX71149, Allosteric regulation, Janssen Pharmaceuticals, Dipraglurant, Research fellow, PAM, Pharmaceutical industry

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

Key Points: 
  • With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
  • In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
  • “The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
  • To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

Retrieved on: 
Mardi, avril 2, 2024
ODD, Research, Growth, Drug discovery, Exercise, NRX, CFO, RNA, Laboratory, Contract research organization, Regenerative medicine, Investigational New Drug, Safety, Spinal cord injury, Intellectual property, Plasma protein binding, Small RNA, FDA, Food, Cryptocurrency

TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.

Key Points: 
  • TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.
  • For the fourth quarter of 2023, expenses were US$0.31 million, compared to US$0.39 million in the previous year.
  • For the fourth quarter of 2023, expenses were US$0.40 million, compared to US$0.46 million in the previous year.
  • For the fourth quarter of 2023, expenses were US$0.02 million, compared to US$0.17 million in the previous year.